Actively Recruiting
Universal 4SCAR7U Targeting CD7-positive Malignancies
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-24
30
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.
CONDITIONS
Official Title
Universal 4SCAR7U Targeting CD7-positive Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 6 months
- Confirmed expression of CD7 and additional surface antigens in cancer cells by immuno-histochemical staining or flow cytometry
- Karnofsky performance status score higher than 80 and life expectancy greater than 3 months
- Adequate bone marrow, liver, and kidney function as shown by cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 times upper limit of normal, AST and ALT ≤ 3 times upper limit of normal, total bilirubin ≤ 2.0 mg/dL
- Hemoglobin level of at least 80 g/L
- No contraindications to cell separation
- Ability to understand and willingness to provide written informed consent
You will not qualify if you...
- Serious illness or medical condition preventing protocol management, including active uncontrolled infection
- Active bacterial, fungal, or viral infection not controlled by treatment
- Known HIV or hepatitis C virus infection
- Pregnant or nursing women
- Use of systemic glucocorticoid therapy within one week before trial entry
- Prior treatment with any gene therapy products
- Inability to comply with study requirements as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, Ph.D
CONTACT
Y
Ying Deng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here